The Sarah Cannon Research Institute UK Drug Development Programme offers consistent performance and excellence through:

- A dedicated, experienced oncology drug development team
- State-of-the-art clinical trials unit in central London
- Competitive start-up timelines
- Rapid patient accrual within a large referral network

**Our Facility**

- CQC-registered oncology trials unit
- On-site pharmacy
- PK testing facilities
- -20 + -80° C freezers
- Refrigerated and non-refrigerated centrifuges
- Cardiac monitoring
- Access to hospital-based critical care services

**For Patients**

- Broad clinical trials portfolio (solid and haematological malignancies)
- Patient-centered support services and referrals
- Private areas for treatment
- On-site catering for patients
- Wireless internet and individual patient entertainment systems

**For Partners**

We are committed to our partners’ goals, and we tailor our teams and processes to meet them, ensuring strong science and consistent quality every step of the way. As collaborators, we strive to provide superior insights that contribute to discovery and success.

**Dedicated Leadership**

Dr Hendrik-Tobias Arkenau, PhD,  
Director, Drug Development Program  
Sarah Cannon Research Institute UK

Matthew Simmons,  
Head of Drug Development Unit  
Sarah Cannon Research Institute UK

**Our Team of Professionals**

We have a fully-staffed nursing and clinical research team including:

- Principal investigators
- Clinical research nurses
- Clinical trial management team
- Quality assurance manager
- Study set-up specialist
- Pharmacists
- Administrative office support

**Facility Amenities and History**

- 13,000 square feet in newly renovated facility
- Registered listed historic building on Harley Street
- Purpose designed unit
- 12 treatment chairs/beds
- Central London location serviced by three main rail stations and Tube

sarahcannonresearch.co.uk
Leadership

Dr Hendrik-Tobias Arkenau, PhD, Director, Drug Development, Sarah Cannon Research Institute UK, has vast experience in early oncology clinical drug development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before joining Sarah Cannon Research Institute UK, he was senior clinical fellow at the Royal Marsden Hospital and team leader for early drug development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.

Contact Information:
Phone: +44 (0) 203 219 5251 • tobias.arkenau@sarahcannonresearch.co.uk

Matthew Simmons, Head of Drug Development Unit, Sarah Cannon Research Institute UK, has extensive operational and commercial experience across all phases of drug development within the pharmaceutical and CRO industries. He has overall responsibility for the day-to-day management of the Sarah Cannon Research Institute UK Drug Development Unit. Matt received his degree in molecular biology from The University of Manchester in 1994, and joined what was then SmithKline Beecham, working on the clinical development of a novel cytotoxic agent. Immediately before joining Sarah Cannon Research Institute UK, he managed the global commercial operations teams for Worldwide Clinical Trials, a mid-sized, full service- CRO.

Contact Information:
Phone: +44 (0) 203 219 5252 • matthew.simmons@sarahcannonresearch.co.uk